Industries / Health / Healthcare / Plasma and blood centers
Plasma for medicines
This work separates donated plasma into purified proteins, such as albumin, clotting factors and immunoglobulin, and turns them into licensed medicines.
7
Milestones achieved, from 1940 to 2021.
2
To watch for: announced, not yet confirmed outside.
2
Open deliverables. Nobody has shipped them.
The road
AchievedWatch forOpen
Achieved
1940
Plasma split into fractions
In the summer of 1940 Edwin Cohn's group at Harvard found a way to split plasma into five main fractions, or groups of proteins, using cold mixtures of ethanol and water; one was albumin, a protein that holds fluid inside the blood vessels. Albumin was flown to Pearl Harbor for burn casualties the day after the attack in December 1941, and by the war's end US companies had turned 2,329,175 donations into more than 570,000 packages of it, by Featherstone and Ball's account.
Credit
Edwin Cohn's group at Harvard, at the request of the US National Research Council
1964
Clotting factor from frozen plasma
In Nature in July 1964 Judith Pool reported that the part of frozen plasma that stays solid when thawed in the cold, later called cryoprecipitate, holds much of factor VIII, the clotting protein that people with haemophilia A lack. Franchini and Mannucci call the finding a major step forward in treating haemophilia.
Credit
Judith Graham Pool, with Edward J. Hershgold and Albert R. Pappenhagen
1980s
Concentrates spread HIV and hepatitis
Factor concentrates, freeze-dried clotting factors made from plasma pooled from about 1,500 to 30,000 donors per commercial pool, by figures given at a 1984 meeting with UK officials, carried HIV and hepatitis viruses to people with bleeding disorders. The UK Infected Blood Inquiry's final report of 20 May 2024 estimates that about 1,250 people with bleeding disorders in the UK, 380 of them children, were infected with HIV, that three quarters of them have died, and that the disaster "could largely, though not entirely, have been avoided".
Lessonpooling plasma from thousands of donors spreads one infected donation to many patients, and the inquiry found "systemic, collective and individual failures" to act on a known risk.
Credit
the Infected Blood Inquiry, chaired by Sir Brian Langstaff
1981
Immunoglobulin for immune diseases
In The Lancet, Paul Imbach and colleagues reported that large doses of immunoglobulin, the antibody fraction of plasma, given into a vein raised the platelet count within 5 days in all 13 children they treated for immune thrombocytopenia, a disease in which the body destroys its own platelets. Immunoglobulin became the "driver" of plasma collection, the product whose demand sets how much plasma is gathered, and by 2022 it made up 60% of a USD 30.3 billion world market for plasma medicines, against 20% of USD 4.8 billion in 1996, by P. Robert's figures cited by von Bonsdorff and colleagues.
Credit
Paul Imbach, Silvio Barandun and colleagues
1985
Solvent and detergent kill viruses
By Bernard Horowitz's account, the US FDA in 1985 licensed the New York Blood Center's haemophilia product treated with a solvent and detergent mix that kills viruses, and more than 60 organizations worldwide adopted the method over the next 15 years. In US figures on people with haemophilia grouped by birth year, Farrugia reports, new infections fell to zero for HIV after 1984 and for hepatitis C after 1992 as heat and solvent–detergent treatments came into use.
Lessonno single step covers every virus, and this one has no effect on so-called non-enveloped viruses, so makers combine it with other safeguards.
Credit
Bernard Horowitz and colleagues, New York Blood Center
1992
Medicines made without plasma
In December 1992 the US FDA approved Baxter's Recombinate, a factor VIII made by genetically engineered cells instead of taken from donated plasma, and Lieuw writes that such recombinant factor VIII has since become the standard in most US and European clinics. The same switch reached tetanus immunoglobulin in 2025, when China's regulator approved Zhuhai Trinomab's siltartoxatug, a cell-made antibody that in a 661-person trial gave 95.4% of recipients protective antibody levels at 12 hours, against 53.2% for the plasma product.
pmc.ncbi.nlm.nih.govfda.govenglish.nmpa.gov.cnpmc.ncbi.nlm.nih.gov
Credit
Baxter Healthcare (Recombinate); Zhuhai Trinomab (siltartoxatug)
2021
Convalescent plasma fails test
In August 2020 the US FDA authorized hospitals to treat COVID-19 patients with plasma from people who had recovered, after a Mayo Clinic-led program had given it to more than 70,000 patients. In May 2021 the UK RECOVERY trial of 11,558 hospital patients found no difference in deaths within 28 days, 24% in both groups.
Lessonwide use outside a randomized trial cannot show whether a treatment works, and one large trial settled what more than 70,000 uncontrolled uses had not.
Credit
RECOVERY Collaborative Group
Watch for
CSL's higher yield per litre
CSL says its Horizon 1 and 2 programs to raise the immunoglobulin made from each litre of plasma "have provided multiple proof points of success", and that the gains "are expected to reduce long-term plasma collection requirements", but it gives no figure in grams per litre.
Achieved whenCSL publishes immunoglobulin yield per litre from before and after the programs, and a regulator or a peer-reviewed study confirms the gain.
Claimed by
CSL, Annual Report 2026, August 2026
Sweden's plasma self-sufficiency plan
Sweden's National Board of Health and Welfare reports that the plasma Sweden collects covers only about 20% of its need for immunoglobulin, and proposes state funding for large-scale plasmapheresis (collecting plasma alone by machine), a national self-sufficiency target and national monitoring.
Achieved whenSweden adopts a national target, and its own published monitoring shows collection covering clearly more than 20% of its immunoglobulin need.
Claimed by
Socialstyrelsen, with the Swedish Medical Products Agency, June 2026
Open
01
A world plasma medicines table
A free, downloadable table of every plasma-derived medicine (albumin, immunoglobulins, clotting factors and others) licensed by at least six regulators: the US FDA, the European Medicines Agency and EU national agencies, Health Canada, Australia's TGA, Japan's PMDA and Brazil's ANVISA. Each row gives the product, active substance, maker and licence date and, where the public label or assessment report states them, the virus-reduction steps and the countries the plasma comes from. Every cell links to its source.
The briefCredit · unclaimed02
An immunoglobulin shortage tracker
A public month-by-month record, from 2015 on, of every official shortage notice for immunoglobulin products in at least eight national registers, for example the US, Canada, the UK, Germany, France, Italy, Australia and Switzerland, plus EMA's EU-wide notices. Each notice gives the product, start and end dates and the stated cause, maps to a common product name, and appears on a chart per country.
The briefCredit · unclaimed
Open 01 · the brief
A world plasma medicines table
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A free, downloadable table of every plasma-derived medicine (albumin, immunoglobulins, clotting factors and others) licensed by at least six regulators: the US FDA, the European Medicines Agency and EU national agencies, Health Canada, Australia's TGA, Japan's PMDA and Brazil's ANVISA. Each row gives the product, active substance, maker and licence date and, where the public label or assessment report states them, the virus-reduction steps and the countries the plasma comes from. Every cell links to its source.
Why it is still open
The FDA's list of fractionated plasma products gives product names only, with no maker, no date and no download, and EMA's plasma master file list gives holders and dates but no plasma origin. The market figures researchers use come from paid Marketing Research Bureau reports, as von Bonsdorff and colleagues note, and GitHub searches for "fractionated plasma products" and "EPAR immunoglobulin" returned no projects (20 November 2026).
Built with what exists
The regulators' public pages and downloads (FDA product pages, EMA's medicine and plasma master file lists, Health Canada's Drug Product Database, Australia's ARTG register) and Python to collect them; an AI model such as Claude to read labels and assessment reports and record each field with a page reference, much as Enveda uses a Claude-based reviewer on drug-making records (Note: "Seven more flagged").
First step
Put the FDA's list of fractionated plasma products and EMA's plasma master file list into one spreadsheet, then add the maker and licence date from each product's own page.
Done looks like
At least 300 product licences across six regulators, every row with a source link, and a published check of 100 randomly chosen rows by a second person, with the error rate stated.
Open 02 · the brief
An immunoglobulin shortage tracker
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A public month-by-month record, from 2015 on, of every official shortage notice for immunoglobulin products in at least eight national registers, for example the US, Canada, the UK, Germany, France, Italy, Australia and Switzerland, plus EMA's EU-wide notices. Each notice gives the product, start and end dates and the stated cause, maps to a common product name, and appears on a chart per country.
Why it is still open
EMA's notice on shortages of human normal immunoglobulins, first published on 3 June 2024 and updated on 22 September 2026, expects them to ease by March 2027 and sends readers to each member state's own register for local status. Public shortage data sets on GitHub cover one country each, the US in Rx Shortage Radar and Canada in rdrugshortages, and a web search found no tracker of immunoglobulin shortages across countries (20 November 2026).
Built with what exists
The registers' own downloads and interfaces where they exist (the FDA shortage feed, Drug Shortages Canada); a browser agent such as Browser Use 1.0 for registers that offer only a search page (Note: "Deleting 80% to start over"); a model that answers fixed yes-or-no questions in bulk, such as Gemini Decision 1, to flag which notices concern immunoglobulin (Note: "A thousand questions, one pass"); Python and a static chart page.
First step
Export every immunoglobulin entry from Drug Shortages Canada and from the FDA's shortage data, and write the shared record format that the other countries will be fitted to.
Done looks like
Eight or more registers covered from 2015 or from their first year online, every notice linked to its source, and a hand check of 200 notices showing that at least 95% are correctly classed.